Percutaneous Coronary Intervention Clinical Trial
Official title:
Holo CTO Proctoring Study
NCT number | NCT05377866 |
Other study ID # | HoloCTO |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 4, 2021 |
Est. completion date | January 31, 2023 |
Verified date | September 2021 |
Source | Sorlandet Hospital HF |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures
Status | Completed |
Enrollment | 10 |
Est. completion date | January 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Clinical inclusion criteria: - Stable angina pectoris, or dyspnoea as an angina equivalent - Age =18 yrs. - Able to provide written informed consent Angiographic inclusion criteria: - One or more completely occluded coronary arteries with Thrombolysis In Myocardial Infarction (TIMI) flow 0. An estimated occlusion duration of at least 3 months - Absence of Q-wave in ECG leads corresponding to the occluded vessel, or documented viability of the main territory by MRI or echocardiography Procedural inclusion criteria: - Clinical indication for CTO PCI regardless of operative technique Exclusion Criteria: - STEMI within 72 hours - Cardiogenic shock - Active bleeding or coagulopathy - Life expectancy < 2 years - Relevant allergies (aspirin, clopidrogrel, ticagrelol, contrast compounds) - Severe peripheral artery disease - Clinical unstable angina |
Country | Name | City | State |
---|---|---|---|
Norway | Sorlandet Hospital | Arendal | Agder |
Lead Sponsor | Collaborator |
---|---|
Sorlandet Hospital HF | HoloCare AS, Oslo University Hospital |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Standard Usability Score on a Likert Scale | The operators completing the intervention will rate the usability of the system on a Likert scale:
The HoloLens was useful in this procedure The HoloLens was not distracting The HoloLens was comfortable to wear The HoloLens camera image has sufficient quality for clinical use (not considering the fluoroscopy screen) Compared to an alternative system with fluoroscopy image plus handsfree voice (telephone), the HoloLens gives additional value during the procedure The current solution with Remote Assist plus parallel fluoroscopy streaming is mature enough for routine use The current solution is stable The current solution is easy to set up prior to the procedure I would like to continue to use the HoloLens in CTO procedures routinely when remote proctoring is needed Agree to Disagree Likert Scale Strongly Disagree Disagree Neither agree nor disagree Agree Strongly Agree |
Procedure duration( aprox 120 min) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Not yet recruiting |
NCT05669222 -
The FAVOR V AMI Trial
|
N/A | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05240781 -
Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk
|
N/A | |
Recruiting |
NCT03378934 -
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
|
Phase 4 | |
Not yet recruiting |
NCT06025071 -
Residual Inflammatory Risk-Guided colcHicine in Elderly Trial
|
Phase 4 | |
Withdrawn |
NCT04043091 -
Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction
|
N/A | |
Completed |
NCT02837744 -
Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
|
||
Completed |
NCT03085823 -
The All-comers Sirolimus-coated Balloon European Registry
|
||
Completed |
NCT02044146 -
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
|
Phase 2/Phase 3 | |
Completed |
NCT03131271 -
Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention
|
N/A | |
Completed |
NCT01135667 -
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
|
Phase 4 | |
Completed |
NCT01156571 -
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
|
Phase 3 | |
Unknown status |
NCT00751491 -
Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
Completed |
NCT00725868 -
Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention
|
N/A | |
Completed |
NCT03708588 -
Chewed Versus Integral Pill of Ticagrelor
|
Phase 4 | |
Completed |
NCT04163393 -
R-One Efficiency For PCI Evolution With Robotic Assistance
|
N/A | |
Recruiting |
NCT05554588 -
Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI
|
N/A | |
Recruiting |
NCT06080919 -
Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI).
|
N/A | |
Recruiting |
NCT05353140 -
LAAO Versus NOAC in Patients With AF and PCI
|
N/A |